Biomarkers: Discovery Techniques and Applications - A Global Market Overview 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Biomarkers: Discovery Techniques and Applications - A Global Market Overview 2019" report has been added to ResearchAndMarkets.com's offering.

The global market for Biomarkers is dominated by Oncology, in terms of application, estimated at a market share of 41.2% in 2018 and forecast to touch US$15.6 billion in 2019. The overall market for Biomarkers is projected to reach approximately US$50 billion by 2021.

The factors driving the Biomarkers market growth includes elevated demand for personalized medicine, technological advancement, immense utilization of biomarkers in drug discovery and development procedures, massive research on biomarkers, increasing awareness about the role of biomarkers in early disease diagnosis, increase research funding, and many more

Research Findings & Coverage

  • The worldwide market for Biomarkers is analyzed in this report with respect to discovery technologies and therapeutic areas/applications
  • Biomarkers' market size is reported in this study by biomarker discovery technologies, therapeutic/applications areas across all major countries
  • Biomarkers Detection by Glycan Antibody Technique
  • Role of Proteomic Techniques in Discovering Gingival Crevicular Fluid Biomarkers
  • Combination of sTRA and CA19-9 Test to Detect Pancreatic Cancer Biomarkers
  • Discovery of Novel Imaging Biomarker for Coronary Inflammation
  • Key business trends focusing on product innovations/developments, M&As, JVs, and other recent industry developments
  • Major companies profiled - 51
  • The industry guide includes the contact details for 225 companies

The report reviews, analyzes and projects the global Biomarkers market for the period 2016-2025 in terms of market value in US$ and the compound annual growth rates (CAGRs) projected from 2018 through 2025

Key Topics Covered:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Product Outline

1.1.1 Biomarkers Defined

1.1.2 Biomarkers in Medicine

1.1.2.1 A History of Biomarkers

1.1.2.2 Biomarkers for Diseases and Biomarkers for Drugs

1.1.2.3 Prerequisites of Biomarkers

1.1.2.4 Categorization of Biomarkers

1.1.2.5 Biomarkers in Drug Development

1.1.2.6 Biomarkers in Diseases

1.1.3 Biomarkers Discovery Technologies

1.1.3.1 Omics Technologies

1.1.3.1.1 Proteomic Methods of Biomarkers Discovery

1.1.3.1.2 Genomic Methods of Biomarkers Discovery

1.1.3.1.3 Metabolomics Methods of Biomarkers Discovery

1.1.3.1.4 Other Omics Technologies for Biomarkers Discovery

1.1.3.2 Imaging Technologies

1.1.3.2.1 Magnetic Resonance Imaging (MRI)

1.1.3.2.2 Computed Tomography (CT)

1.1.3.2.3 Ultrasound (US)

1.1.3.2.4 X-Rays

1.1.3.2.5 Positron Emission Tomography (PET)

1.1.3.2.6 Single Photon Emission Computed Tomography (SPECT)

1.1.3.2.7 Others

1.1.3.3 Bioinformatics

1.1.4 Therapeutic Areas for Biomarkers

1.1.4.1 Cancer Biomarkers

1.1.4.1.1 Cancer Biomarkers Defined

1.1.4.1.2 Functions of Biomarkers in Cancer Medicine

1.1.4.1.3 Functions of Biomarkers in Cancer Research

1.1.4.1.4 Categories of Cancer Markers

1.1.4.2 Cardiac Biomarkers

1.1.4.2.1 Measurement Applications of Cardiac Biomarkers

1.1.4.2.2 Classes of Cardiac Marker Tests

1.1.4.2.3 Biomarkers of Coronary Artery Disease

1.1.4.2.4 Role Played by Innovative Multiple Biomarkers in Predicting Cardiovascular Outcomes

1.1.4.3 Biomarkers for Neurological Disorders

1.1.4.4 Other Therapeutic Areas for Biomarkers

1.1.4.4.1 Biomarkers of Diabetes

1.1.4.4.2 Biomarkers of Aging

2. KEY MARKET TRENDS

2.1 Biomarkers Detection by Glycan Antibody Technique

2.2 Role of Proteomic Techniques in Discovering Gingival Crevicular Fluid Biomarkers Proteomic Technology (GC/MS, MALDI-TOF MS, and LC-MS/MS)

2.3 Novel Biomarkers May Assist Rapid Diagnosis of Autism

2.4 Detection of Autoimmune and Inflammatory Disorders Using Aberrant Non-Coding RNA

2.5 Abnormal miRNA Expression Profiles of T Cells Acts as Biomarkers of Pathogenesis and Ailment in SLE Sufferers

2.6 Combination of sTRA and CA19-9 Test to Detect Pancreatic Cancer Biomarkers

2.7 Proteomics Application to Discover Serum Biomarkers of Kawasaki Disease

2.8 Novel Rheumatoid Arthritis Biomarkers Detected by Researchers

2.9 Discovery of New Kidney Cancer Biomarkers

2.10 Correlation of Novel Inflammatory Biomarkers with Elevated Thrombosis Risk in Cancer Survivors

2.11 Identification of Biomarker for Widespread Heart Failure Type

2.12 Discovery of Novel Imaging Biomarker for Coronary Inflammation

2.13 A Novel Biomarker Based Bioimaging Approach for Kidney Cancer Cell Assessment

2.14 New Biomarker and Therapy for Melanoma has Been Discovered by BU Investigators

2.15 microRNA Signature - A Novel Biomarker Discovered for Postoperative Liver Disorder

3. KEY GLOBAL PLAYERS

  • Abbott Diagnostics (United States)
  • Agendia NV (The Netherlands)
  • Agilent Technologies, Inc. (United States)
  • Asuragen, Inc. (United States)
  • Beckman Coulter, Inc. (United States)
  • Biocartis NV (Belgium)
  • bioMrieux SA (France)
  • Bio-Rad Laboratories, Inc. (United States)
  • Bruker Corporation (United States)
  • Caprion Biosciences, Inc. (Canada)
  • Charles River Laboratories, Inc. (United States)
  • Cisbio Bioassays (France)
  • EKF Diagnostics Holdings Plc (United Kingdom)
  • Enzo Biochem, Inc. (United States)
  • Epigenomics AG (Germany)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GE Healthcare (United States)
  • Genedata AG (Switzerland)
  • Genomic Health, Inc. (United States)
  • Human Metabolome Technologies (Japan)
  • Illumina, Inc. (United States)
  • Janssen Pharmaceutica NV (Belgium)
  • Koninklijke Philips N.V (The Netherlands)
  • Meso Scale Diagnostics LLC. (United States)
  • Metabolon, Inc. (United States)
  • MilliporeSigma (United States)
  • Myriad Genetics, Inc. (United States)
  • NanoString Technologies, Inc. (United States)
  • Nexus Dx (United States)
  • PerkinElmer, Inc. (United States)
  • Pharmaceutical Product Development LLC (United States)
  • QIAGEN B.V. (The Netherlands)
  • Rosetta Genomics (Israel)
  • Siemens Healthineers (Germany)
  • Singulex, Inc. (United States)
  • Thermo Fisher Scientific, Inc.(United States)
  • Waters Corporation (United States)

4. KEY BUSINESS AND PRODUCT TRENDS

5. GLOBAL MARKET OVERVIEW

5.1 Global Biomarkers Market Overview by Discovery Technology

5.1.1 Global Omics Technologies for Biomarkers Market Overview by Segment

5.1.1.1 Omics Technology Segments Market Overview by Global Region

5.1.1.1.1 Proteomics

5.1.1.1.2 Genomics

5.1.1.1.3 Metabolomics

5.1.1.1.4 Other Omics Technologies

5.1.2 Global Bioimaging Market Overview by Modality

5.1.2.1 Bioimaging Modalities Market Overview by Global Region

5.1.2.1.1 MRI

5.1.2.1.2 CT

5.1.2.1.3 Ultrasound

5.1.2.1.4 Other Bioimaging Modalities

5.1.3 Biomarkers Discovery Technology Market Overview by Global Region

5.1.3.1 Omics Technologies

5.1.3.2 Bioimaging

5.1.3.3 Bioinformatics

5.2 Global Biomarkers Market Overview by Therapeutic Area

5.2.1 Biomarkers Therapeutic Area Market Overview by Global Region

5.2.1.1 Oncology

5.2.1.2 Cardiology

5.2.1.3 Neurology

5.2.1.4 Other Therapeutic Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

6. NORTH AMERICA

Major Market Players

  • Abbott Diagnostics (United States)
  • Agilent Technologies, Inc. (United States)
  • Altheadx, Inc. (United States)
  • Asuragen, Inc. (United States)
  • Banyan Biomarkers, Inc. (United States)
  • Beckman Coulter, Inc. (United States)
  • BG Medicine, Inc. (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • Bruker Corporation (United States)
  • Caprion Biosciences, Inc. (Canada)
  • Charles River Laboratories, Inc. (United States)
  • ENZO Biochem, Inc. (United States)
  • GE Healthcare (United States)
  • Genomic Health, Inc. (United States)
  • Illumina, Inc. (United States)
  • Life Diagnostics, Inc. (United States)
  • Lifesign LLC. (United States)
  • Meso Scale Diagnostics LLC. (United States)
  • Metabolon, Inc. (United States)
  • Milliporesigma (United States)
  • Myriad Genetics, Inc. (United States)
  • Myriad RBM (United States)
  • Nanostring Technologies, Inc. (United States)
  • Nexus DX (United States)
  • Perkinelmer, Inc. (United States)
  • Pharmaceutical Product Development LLC (United States)
  • Shimadzu Scientific Instruments (United States)
  • Signosis, Inc. (United States)
  • Singulex, Inc. (United States)
  • Stagezero Life Sciences, Inc. (Canada)
  • Thermo Fisher Scientific, Inc. (United States)
  • Waters Corporation (United States)

EUROPE

Major Market Players

  • Agendia Nv (The Netherlands)
  • Akuru Pharma AB (Sweden)
  • Bayer Pharma AG (Germany)
  • Biocartis NV (Belgium)
  • Biomrieux SA (France)
  • Biosystems International Kft (Hungary)
  • Cisbio Bioassays (France)
  • Decode Genetics (Iceland)
  • EKF Diagnostics Holdings Plc (United Kingdom)
  • Epigenomics AG (Germany)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Genedata AG (Switzerland)
  • Janssen Pharmaceutica NV (Belgium)
  • Koninklijke Philips N.V (The Netherlands)
  • Pamgene International B.V. (The Netherlands)
  • Qiagen B.V. (The Netherlands)
  • Siemens Healthineers (Germany)

For more information about this report visit https://www.researchandmarkets.com/r/o5kuyw

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900